Roland S. Liblau, MD, PhD

Investigation of the effects of IVIg in a mouse model of autoimmune narcolepsy
Professor Liblau's group recently developed a mouse model to investigate the autoimmune processes occurring in idiopathic narcolepsy. Using this model, the T cell responses against the hypocretin/orexin-producing neurons involved in sleep/wake regulation can be tested. Within the scope of this project, it is being tested which autoreactive T cell populations (CD8+, Th1, Th17, and combination of different T-cell populations) can induce this disabling disease using genetically modified mice. Since intravenous immunoglobulins (IVIg) have been shown in some patients to efficiently reduce narcolepsy symptoms, the main objective is now to study the modulating effects of IVIg on components of the cellular immune response in our novel experimental model.

Curriculum vitae of Roland Linblau MD, PhD

Since 2011, Professor Roland Liblau has been the director of the Physiopathology Research Center of Toulouse-Purpan, France. Before moving to Toulouse, he was working at INSERM Paris, where he was head of the Neuro-Immunology Research Team, from 1996 to 2002. Since 2001 he has been professor of clinical immunology in Toulouse, France where he headed the Autoimmunity and Immunoregulation Research Team from 2003 to 2009. From 2009 to 2011, he was a deputy director of the Pathophysiology Research Center of Toulouse Purpan.
Dr. Liblau's main scientific interests are the study of CD8+-T, CD4+-T and NK-T cells, cytokines and cytokine receptors and tumor necrosis factor α (TNF-α) in various autoimmune diseases, such as diabetes mellitus type 1 and multiple sclerosis (MS), and in experimental autoimmune diseases.